度洛西汀预防急性冠脉综合征患者抑郁的效果（DECARD）。
Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD).
机构信息
Liaison Psychiatry Unit, Mental Health Centre Copenhagen, Bispebjerg University Hospital, Copenhagen, Denmark.
出版信息
J Psychosom Res. 2012 Jan;72(1):11-6. doi: 10.1016/j.jpsychores.2011.07.001. Epub 2011 Sep 3.
OBJECTIVE
Depression is a major problem in patients after acute coronary syndrome (ACS) with negative impact on survival and quality of life. No studies have examined prevention of post-ACS depression. We examined whether treatment with escitalopram can prevent post-ACS depression.
METHODS
We have conducted a randomised controlled trial. Between November 2004 and December 2007, 240 patients in 2 university hospitals in Copenhagen, Denmark, with ACS were randomised. Patients were randomised to a double-blind treatment with escitalopram or matching placebo for 1 year. Main outcome measure was the incidence of ICD-10 depressive episode.
RESULTS
Of 120 patients treated with escitalopram 2 developed depression versus 10 in placebo treated group (log rank, p=0.022). In multivariate analysis treatment with placebo and high Hamilton Depression Scale score at baseline were associated with development of depression. Patients were well matched at baseline.
CONCLUSION
Twelve months treatment with escitalopram prevented depression in post-ACS patients.
目的
抑郁是急性冠状动脉综合征（ACS）后患者的一个主要问题，对生存和生活质量有负面影响。目前尚无研究探讨 ACS 后抑郁的预防。我们研究了艾司西酞普兰治疗是否可以预防 ACS 后抑郁。
方法
我们进行了一项随机对照试验。2004 年 11 月至 2007 年 12 月，丹麦哥本哈根的 2 所大学医院纳入了 240 例 ACS 患者。患者被随机分配至接受艾司西酞普兰或匹配安慰剂治疗 1 年的双盲治疗。主要结局指标为 ICD-10 抑郁发作的发生率。
结果
艾司西酞普兰治疗的 120 例患者中有 2 例发生抑郁，安慰剂治疗组有 10 例（对数秩检验，p=0.022）。多变量分析显示，安慰剂治疗和基线时汉密尔顿抑郁量表评分较高与抑郁的发生相关。患者在基线时匹配良好。
结论
艾司西酞普兰治疗 12 个月可预防 ACS 后患者的抑郁。
Zotero 插件